Literature DB >> 24975553

L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.

Yong Wang1, Hui Sheng Wang, Tao Wang, Chen Huang, Jian Liu.   

Abstract

L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is the most common complication of standard L-DOPA therapy for Parkinson's disease experienced by most parkinsonian patients. LID is associated with disruption of dopaminergic homeostasis in basal ganglia following L-DOPA administration. Norepinephrine (NE) is another important catecholaminergic neurotransmitter that is also believed to be involved in the pathogenesis of LID. This study compared NE release in the ipsilateral sensorimotor striatum of dyskinetic and nondyskinetic 6-hydroxydopamine-lesioned hemiparkinsonian rats treated chronically with L-DOPA. After L-DOPA injection, the time-course curves of NE levels in the sensorimotor striatum were significantly different between dyskinetic and nondyskinetic rats. Several metabolic kinetic parameters of NE levels were also differentially expressed between the two groups. In comparison with nondyskinetic rats, the ΔCmax of NE was significantly higher in dyskinetic rats, whereas Tmax and t1/2 of NE were significantly shorter. Intrastriatal perfusion of NE into the lesioned sensorimotor striatum revealed a moderate dyskinesia in dyskinetic rats, which was similar to the dyskinetic behavior after L-DOPA administration. The L-DOPA-related dyskinetic behavior was inhibited significantly by a further pretreatment of noradrenergic neurotoxin N-​(2-​chloroethyl)​-​N-​ethyl-​2-​bromobenzylamine or intrastriatal administration of the α2 -adrenoceptor antagonist idazoxan, accompanied by significant changes in metabolic kinetic parameters of NE in the sensorimotor striatum. The results provide evidence to support the correlation between abnormal NE neurotransmission and the induction of LID and suggest that the aberrant change of the quantitative and temporal releasing of NE in the sensorimotor striatum might play an important role in the pathogenesis of LID.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  L-DOPA; Parkinson's disease; microdialysis; norepinephrine; striatum

Mesh:

Substances:

Year:  2014        PMID: 24975553     DOI: 10.1002/jnr.23439

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

2.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

3.  Quantitative motor assessment of dyskinesias in Parkinson's disease.

Authors:  Eva Schaeffer; Walter Maetzler; Inga Liepelt-Scarfone; Christian Sass; Ralf Reilmann; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2015-02-25       Impact factor: 3.575

4.  Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Authors:  Kinga Kamińska; Tomasz Lenda; Jolanta Konieczny; Elżbieta Lorenc-Koci
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

Review 5.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Authors:  M Angela Cenci
Journal:  Front Neurol       Date:  2014-12-15       Impact factor: 4.003

Review 6.  Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.

Authors:  Juan-Juan Du; Sheng-Di Chen
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

Review 7.  The Noradrenergic System in Parkinson's Disease.

Authors:  Elena Paredes-Rodriguez; Sergio Vegas-Suarez; Teresa Morera-Herreras; Philippe De Deurwaerdere; Cristina Miguelez
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

8.  Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia.

Authors:  Shasha Gao; Rui Gao; Lu Yao; Jie Feng; Wanyuan Liu; Yingqiong Zhou; Qiongchi Zhang; Yong Wang; Jian Liu
Journal:  Front Aging Neurosci       Date:  2022-02-03       Impact factor: 5.750

Review 9.  L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.

Authors:  Abdeslam Chagraoui; Marie Boulain; Laurent Juvin; Youssef Anouar; Grégory Barrière; Philippe De Deurwaerdère
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.